EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial

Alexandra F Freeman, Corina E Gonzalez, Bonnie Yates, Kristen Cole, Lauren Little, Erin Flannelly, Seth M Steinberg, George Mo, Nicole Piette, Thomas E Hughes, Jennifer Cuellar-Rodriguez, Juan Gea-Banacloche und 11 weitere

Journal of Allergy and Clinical Immunology · 2025

DOI: 10.1016/j.jaci.2024.08.021 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Alexandra F Freeman und 22 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Md. Hauptthemen laut MEDLINE: Graft vs Host Disease, Guanine Nucleotide Exchange Factors, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: DOCK8 deficiency is a primary immunodeficiency in which allogeneic hematopoietic cell transplantation (HCT) represents the only known cure. We tested the ability of a busulfan-based regimen to achieve reliable engraftment and high levels of donor chimerism with acceptable toxicity in a prospective clinical trial in DOCK8 deficiency. OBJECTIVES: To both evaluate the ability of HCT to reverse the clinical phenotype and to correct the immunologic abnormalities by 1 year post HCT. METHODS: We conducted a prospective HCT trial for recipients with DOCK8 deficiency. Subjects were recruited from October 5, 2010, to December 30, 2022. Donor sources included fully matched related and unrelated donors and haploidentical donors. The reduced toxicity, myeloablative conditioning regimen contained no serotherapy. Graft-versus-host disease (GVHD) prophylaxis included either a calcineurin inhibitor with methotrexate or post-HCT cyclophosphamide (PT/Cy) followed by tacrolimus and mycophenolate mofetil. The trial was later amended to study PT/Cy in all patients. (Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 [NCT01176006].) RESULTS: Thirty-six subjects, both children and adults (median age 16.4 years), underwent HCT for DOCK8 deficiency. Most patients, 33 of 36 (92%), achieved full (≥98%) donor chimerism in whole blood as early as day +30. With a median potential follow-up of 7.4 years, 29 (80.6%) were alive with no evidence of new DOCK8 deficiency-related complications. PT/Cy was effective in reducing the risk of acute GVHD in patients who had received matched unrelated donor and haploidentical transplants, but it was associated with transient delays in immune-reconstitution and hemorrhagic cystitis. CONCLUSIONS: A busulfan-based HCT regimen using PT/Cy for GVHD prophylaxis and a broad range of donor types and hematopoietic cell sources were well tolerated, leading to the reversal of the clinical immunophenotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseGuanine Nucleotide Exchange FactorsHematopoietic Stem Cell TransplantationTransplantation ConditioningAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultBusulfanPrimary Immunodeficiency DiseasesProspective Studies

Stichwörter der Autor:innen

DOCK8 deficiencyhematopoietic cell transplantationimmunophenotype reversal

Substanzen

BusulfanDOCK8 protein, humanGuanine Nucleotide Exchange Factors

Autor:innen und Institutionen

  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Md.
  • Immune-Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, Md. Electronic address: corina.gonzalez@nih.gov.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Md.
  • Transplant and Cell Therapy Program, Clinical Center, Bethesda, Md.
  • Immune-Deficiency Cellular Therapy Program, National Cancer Institute, Bethesda, Md.
  • Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Md.

Förderung

  • Intramural NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • U.S. Department of Health and Human Services
  • Center for Cancer Research
  • Clinical Center
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Freeman, A. F., Gonzalez, C. E., Yates, B., Cole, K., Little, L., Flannelly, E., Steinberg, S. M., Mo, G., Piette, N., Hughes, T. E., Cuellar-Rodriguez, J., Gea-Banacloche, J., Heller, T., Hammoud, D. A., Holland, S. M., Kong, H. H., Young, F. D., Jing, H., Kayaoglu, B., …, & Shah, N. N. (2025). Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.08.021

Vancouver

Freeman AF, Gonzalez CE, Yates B, Cole K, Little L, Flannelly E, et al. Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2024.08.021

BibTeX
@article{Freeman2025,
  author = {Freeman, Alexandra F and Gonzalez, Corina E and Yates, Bonnie and Cole, Kristen and Little, Lauren and Flannelly, Erin and Steinberg, Seth M and Mo, George and Piette, Nicole and Hughes, Thomas E and Cuellar-Rodriguez, Jennifer and Gea-Banacloche, Juan and Heller, Theo and Hammoud, Dima A and Holland, Steve M and Kong, Heidi H and Young, Fernanda D and Jing, Huie and Kayaoglu, Basak and Su, Helen C and Pai, Sung-Yun and Hickstein, Dennis D and Shah, Nirali N},
  title = {Hematopoietic cell transplantation for DOCK8 deficiency: Results from a prospective clinical trial},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.jaci.2024.08.021}
}
Kostenlos starten →